Pyrimidine compound as JAK kinase inhibitor
US10774080B2 · kind B2 · utility
5Cited by
13References
22Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 8, 2020 |
| Grant date | Sep 15, 2020 |
| Priority date | — |
| Expiry date | Jan 8, 2040 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07B2200/13
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides a compound of formula (I): or a pharmaceutically-acceptable salt thereof, that is an inhibitor of JAK kinases. The invention also provides pharmaceutical compositions comprising such compound, a crystalline form, methods of using such compound to treat inflammatory skin diseases and other diseases, and processes and intermediates useful for preparing such compound.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.